EGFLAM antibody (AA 25-300)

Catalog No. ABIN7163453

This Rabbit Polyclonal antibody specifically detects EGFLAM in WB and ELISA. It exhibits reactivity toward Human.

Quick Overview for EGFLAM antibody (AA 25-300) (ABIN7163453)

Target: EGFLAM (EGF-Like, Fibronectin Type III and Laminin G Domains (EGFLAM))

Reactivity: Human

Host: Rabbit

Clonality: Polyclonal

Conjugate: This EGFLAM antibody is un-conjugated

Application: Western Blotting (WB), ELISA

Product Details anti-EGFLAM Antibody

Binding Specificity: AA 25-300

Purpose: EGFLAM Antibody

Cross-Reactivity: Mouse

Purification: Protein G purified

Purity: >95 %

Immunogen: Recombinant Human Pikachurin protein (25-300AA)

Isotype: IgG

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Handling

Format: Liquid

Buffer: Preservative: 0.03 % Proclin 300
Constituents: 50 % Glycerol, 0.01M PBS, PH 7.4

Preservative: ProClin

Precaution of Use: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: -20 °C,-80 °C

Storage Comment: Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.

Target Details for EGFLAM

Target: EGFLAM (EGF-Like, Fibronectin Type III and Laminin G Domains (EGFLAM))

Alternative Name: EGFLAM

Background:

Background: Involved in both the retinal photoreceptor ribbon synapse formation and physiological functions of visual perception. Necessary for proper bipolar dendritic tip apposition to the photoreceptor ribbon synapse. Promotes matrix assembly and cell adhesiveness.

Aliases: Agrin-like protein antibody, AGRINL antibody, AGRNL antibody, EGF-like antibody, EGF-like, fibronectin type III and laminin G domains antibody, EGF-like, fibronectin type-III and laminin G-like domain-containing protein antibody, EGFLA_HUMAN antibody, EGFLAM antibody, fibronectin type-III and laminin G-like domain-containing protein antibody, FLJ39155 antibody, Pikachurin antibody

UniProt: Q63HQ2

Pathways: Glycosaminoglycan Metabolic Process